Basic Characteristics of Muse Cells - PubMed

Review

Basic Characteristics of Muse Cells

Shohei Wakao et al. Adv Exp Med Biol. 2018.

Erratum in

• Correction to: Basic Characteristics of Muse Cells.

  Wakao S, Kushida Y, Dezawa M. Wakao S, et al. Adv Exp Med Biol. 2018;1103:C1. doi: 10.1007/978-4-431-56847-6_19. Adv Exp Med Biol. 2018. PMID: 31236853

Abstract

Multilineage-differentiating stress-enduring (Muse) cells exhibit the core characteristics of pluripotent stem cells, namely, the expression of pluripotency markers and the capacity for trilineage differentiation both in vitro and in vivo and self-renewability. In addition, Muse cells have unique characteristics not observed in other pluripotent stem cells such as embryonic stem cells, control of pluripotency by environmental switch of adherent suspension, symmetric and asymmetric cell division, expression of factors relevant to stress tolerance, and distinctive tissue distribution. Pluripotent stem cells were recently classified into two discrete states, naïve and primed. These two states have multiple functional differences, including their proliferation rate, molecular properties, and growth factor dependency. The properties exhibited by Muse cells are similar to those of primed pluripotent stem cells while with some uniqueness. In this chapter, we provide a comprehensive description of the basic characteristics of Muse cells.

Keywords: Bone marrow; Cluster; Connective tissue; DNA repair; Peripheral blood; Primed pluripotent; SSEA-3; Self-renewal; Suspension; Trilineage differentiation.

Similar articles

• The Muse Cell Discovery, Thanks to Wine and Science.

  Dezawa M. Dezawa M. Adv Exp Med Biol. 2018;1103:1-11. doi: 10.1007/978-4-431-56847-6_1. Adv Exp Med Biol. 2018. PMID: 30484221 Review.

• Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): a seven-year retrospective.

  Fisch SC, Gimeno ML, Phan JD, Simerman AA, Dumesic DA, Perone MJ, Chazenbalk GD. Fisch SC, et al. Stem Cell Res Ther. 2017 Oct 18;8(1):227. doi: 10.1186/s13287-017-0674-3. Stem Cell Res Ther. 2017. PMID: 29041955 Free PMC article. Review.

• Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1.

  Gimeno ML, Fuertes F, Barcala Tabarrozzi AE, Attorressi AI, Cucchiani R, Corrales L, Oliveira TC, Sogayar MC, Labriola L, Dewey RA, Perone MJ. Gimeno ML, et al. Stem Cells Transl Med. 2017 Jan;6(1):161-173. doi: 10.5966/sctm.2016-0014. Epub 2016 Aug 2. Stem Cells Transl Med. 2017. PMID: 28170177 Free PMC article.

• Study of the protective effect on damaged intestinal epithelial cells of rat multilineage-differentiating stress-enduring (Muse) cells.

  Sun D, Yang L, Cao H, Shen ZY, Song HL. Sun D, et al. Cell Biol Int. 2020 Feb;44(2):549-559. doi: 10.1002/cbin.11255. Epub 2019 Nov 6. Cell Biol Int. 2020. PMID: 31642560 Free PMC article.

• Muse cells, newly found non-tumorigenic pluripotent stem cells, reside in human mesenchymal tissues.

  Wakao S, Akashi H, Kushida Y, Dezawa M. Wakao S, et al. Pathol Int. 2014 Jan;64(1):1-9. doi: 10.1111/pin.12129. Pathol Int. 2014. PMID: 24471964 Review.

Cited by

• Characteristics of multilineage-differentiating stress-enduring cell clusters in different culture conditions.

  Ning J, Cao YY, Zhang RZ, Li Y. Ning J, et al. Skin Res Technol. 2023 Nov;29(11):e13528. doi: 10.1111/srt.13528. Skin Res Technol. 2023. PMID: 38009041 Free PMC article.

• Adipose Tissue: Understanding the Heterogeneity of Stem Cells for Regenerative Medicine.

  Ong WK, Chakraborty S, Sugii S. Ong WK, et al. Biomolecules. 2021 Jun 22;11(7):918. doi: 10.3390/biom11070918. Biomolecules. 2021. PMID: 34206204 Free PMC article. Review.

• Signaling domains of cancer-associated glycolipids.

  Furukawa K, Ohmi Y, Hamamura K, Kondo Y, Ohkawa Y, Kaneko K, Hashimoto N, Yesmin F, Bhuiyan RH, Tajima O, Furukawa K. Furukawa K, et al. Glycoconj J. 2022 Apr;39(2):145-155. doi: 10.1007/s10719-022-10051-1. Epub 2022 Mar 22. Glycoconj J. 2022. PMID: 35315508 Review.

• Cell-based treatment for perinatal hypoxic-ischemic encephalopathy.

  Park YJ, Borlongan CV, Dezawa M. Park YJ, et al. Brain Circ. 2021 Mar 30;7(1):13-17. doi: 10.4103/bc.bc_7_21. eCollection 2021 Jan-Mar. Brain Circ. 2021. PMID: 34084971 Free PMC article. Review.

• Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial.

  Koda M, Imagama S, Nakashima H, Ito S, Segi N, Ouchida J, Suda K, Harmon Matsumoto S, Komatsu M, Endo T, Suzuki S, Inami S, Ueda H, Miyagi M, Inoue G, Takaso M, Nagata K, Yamada H, Kamei N, Nakamae T, Suzuki H, Nishida N, Funaba M, Kumagai G, Furuya T, Yamato Y, Funayama T, Takahashi H, Yamazaki M. Koda M, et al. Stem Cell Res Ther. 2024 Aug 13;15(1):259. doi: 10.1186/s13287-024-03842-w. Stem Cell Res Ther. 2024. PMID: 39135172 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer